HLA-G and plasma cell myeloma: Aberrant HLA-G expression was also described in other hematological malignancies such as non-Hodgkin lymphoma (Sebti et al. 2007), chronic lymphatic leukemia (Sebti et al. 2007), and multiple myeloma (Leleu et al. 2005) as well as in solid tumors, such as breast cancer (Konig et al. 2016; Rebmann et al. 2003), and non-small cell lung cancer, particularly in advanced disease stages (Ben Amor et al. 2016; Yan et al. 2015).